[A phase I trial of 4'-epiadriamycin].
A phase I study of a new anthracycline, 4'-epiadriamycin was conducted in a total of 28 patients with various advanced cancers refractory to standard chemotherapies and 26 were evaluable. A dose limiting factor was leukopenia reaching a nadir approximately 2 weeks later and about one week needed for the recovery. Thrombocytopenia was milder and less frequent than leukopenia but dose-related. Nausea and alopecia were observed in the majority of patients but vomiting was relatively rare and therefore non-hematologic toxicities were judged to be milder than adriamycin. A recommended dose for patients having prior extensive chemotherapies was determined to be 60 mg/m2 in 3 weeks intervals.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin